Macro Dashboard — 2026-11-05
| Indicator | Level | 5-Day Δ | Signal |
|---|---|---|---|
| KOSPI | 5,383.8 | −6.1% | Bear |
| KOSDAQ | 678.4 | −6.4% | Bear |
| VIX | 16.82 | −2.2% | Stable |
| US 10Y | 4.89% | −0.09pp | Flat |
| USD/KRW | 1,342.8 | +0.4% | Flat |
| Brent | $96.2 | −8.2% | Falling |
| DXY | 101.5 | −0.7% | Flat |
Regime: KR Bear | US Bull (11/12 inputs verified). Only 16.7% of Korean stocks trade above their 50-day moving average; 40.3% of US stocks do. VIX at 16.8 and US yields drifting lower confirm this is a Korea-specific drawdown, not a global risk-off event.
Market Wrap
Korea’s November 5 session was a broad, technically-driven sell-off with two distinct pockets of institutional support cutting against the tide.
The aggregate picture leaves little room for interpretation: 1,714 stocks fell, 635 rose, and the average stock declined 1.96%. Program selling totaled ₩1.69 trillion net while ETF redemptions reached ₩1.52 trillion. Futures basis sat at −0.53. This is systematic passive de-risking — not a single-sector event.
Where money entered. Internet and platform names were the session’s standout. NAVER (035420.KS, +8.26%) attracted simultaneous foreign and institutional net buying — a rare alignment on a down day. Kakao (035720.KS, +10.65%) drew the heaviest foreign inflows of any name. Hybe (352820.KS, +8.19%) also saw foreign accumulation. The likely driver: falling oil prices and stabilizing US yields created a rotation window into domestic internet names that had lagged through October.
Financials were the second destination for institutional flows. KB Financial (105560.KS, +3.63%), Woori Financial (316140.KS, +5.27%), Hyundai Mobis (012330.KS, +2.54%), Hyundai Motor (005380.KS, +3.53%), and Hana Financial (086790.KS, +3.16%) all recorded institutional net buying. Samsung Biologics (207940.KS, +1.67%) was bought by institutions even as foreign investors trimmed. Koryo Zinc (010130.KS, +11.0%) surged with institutional support; foreign investors were on the other side.
Where money exited. Semiconductors and the battery supply chain bore the heaviest institutional selling. PSK Holdings (031980.KS, −19.4%), Lotte Energy Materials (020150.KS, −18.4%), Doosan (000150.KS, −17.5%), TES (095610.KS, −17.1%), and Doosan Tesna (131970.KS, −16.1%) all saw combined foreign and institutional selling. Samsung SDI (006400.KS, −6.6%) and S-Oil (010950.KS, −6.2%) declined as institutions distributed. The common thread across the losers: capex-intensive businesses where slowing order visibility or margin pressure makes the near-term earnings trajectory harder to defend.
The split is clean. Quality internet and financial franchises absorbed institutional flows; semis, batteries, and energy supply chain were the exits. With KOSPI and KOSDAQ both trading more than 20% below their 200-day moving averages, the structural backdrop remains broken. But within that environment, some businesses are being selectively re-priced higher.
Note: Same-day full close briefing unavailable; this section is sourced from the same-day Research OS market snapshot.
Today’s Quality Re-Rating Candidates
The KR Meta Screener evaluated 109 tickers and ranked 20 article candidates for November 5. The PEAD screener produced no 2+ overlap candidates on its own today. The meta screener’s multi-family scoring identifies the stronger setups, where quality fundamentals, money flow, and an earnings or cycle catalyst converge.
Top Candidates (Meta Screener Rank)
| Rank | Ticker | Name | Meta Score | Families | Screeners Hit |
|---|---|---|---|---|---|
| 1 | 086450.KS | Dongkook Pharmaceutical | 76.7 | 4 | Quality, Cycle Rerating, PEAD, Quiet Accumulation, RS80 |
| 2 | 128940.KS | Hanmi Pharma | 53.8 | 2 (5 evidence) | Smart Money Quality, Cycle Rerating, Consensus Up, Smart Money Earnings |
| 3 | 011200.KS | HMM | 36.8 | 3 | Consensus Up, Quiet Accumulation, RS80 |
| 4 | 089860.KS | Lotte Rental | 35.6 | 3 | Cycle Rerating, Quiet Accumulation, RS80 + same-day DART prelim |
| 5 | 036460.KS | KOGAS | 30.6 | 2 (5 evidence) | Quiet Accumulation, RS80, Kiwoom surface + buyback DART |
| 6 | 030000.KS | Cheil Worldwide | 29.6 | 2 (4 evidence) | Quiet Accumulation, RS80 + same-day DART prelim |
| 7 | 071970.KS | HD Hyundai Marine Engine | 19.7 | 2 (4 evidence) | Consensus Up, Kiwoom surface + 3 DART catalysts |
| 8 | 089590.KS | Jeju Air | 22.8 | 1 (3 evidence) | Consensus Up (z +5.88), IR event DART |
Top 3 in Detail
#1 — Dongkook Pharmaceutical (086450.KS, Score 76.7)
Dongkook is a mid-cap Korean pharma spanning OTC topical drugs, prescription products, and health supplements. It leads today’s candidates because it registers across the most independent screener families: Quality Compounder (ROE 9.9%, operating profit YoY +20.1%), Cycle Rerating (margin expansion +0.5pp), Quiet Accumulation (foreign ownership rising in a compressed price range, retail selling ₩7.6bn absorbed by institutional and foreign buyers), RS80 not-late leadership (MA50 premium +10.5%, 20-day flow momentum +22%), and Tier C of the PEAD screener (OP growth +20%, margin +0.52pp). The convergence of quality fundamentals and quiet buying pressure in a down market is the signal. Key caveat: the PEAD financial data is based on FY2025Q4 (filing age 238 days). The next verification is a fresh 1H2026 earnings release that either confirms or cancels the margin expansion story.
#2 — Hanmi Pharma (128940.KS, Score 53.8)
Hanmi is one of Korea’s most active drug-licensing platforms, with a deepening pipeline in obesity and rare diseases. Today it hits Smart Money Quality (net foreign + institutional buying of ₩60.3bn over five days), Cycle Rerating (margin expansion +2.2pp — the strongest margin signal among all candidates today), Consensus Up Revision, and Smart Money Earnings. Retail sold ₩55bn; institutional and foreign absorbed. A live DART catalyst reinforces the picture: an October 30 technology-transfer agreement for the Fabry disease treatment LAGLA. The core question for follow-up research is whether the consensus revision is driven by this single licensing event — making it one-time — or by underlying pipeline momentum that sustains the margin improvement into 2H2026.
#3 — HMM (011200.KS, Score 36.8)
HMM is Korea’s largest container shipping company. It qualifies via Consensus Up Revision (composite z-score +0.53), Quiet Accumulation (foreign ownership rising in a narrow price range, retail selling ₩34.6bn absorbed by institutional and foreign flows), and RS80 Not-Late Leadership (pivot gap +6.9%, Focus Candidate classification, 20-day supply-demand momentum +22.5%). A DART disclosure filed October 15 shows new facility investment, potentially signaling fleet expansion plans. With Brent crude falling 8.2% over five days, shipping input costs are easing — a potential margin tailwind that may explain the consensus upgrade. The critical next check is whether spot shipping rates (BDI, CCFI) are recovering to validate the earnings revision, or whether the upgrade is running ahead of fundamentals.
Source: Research OS macro-regime data (11/12 inputs current), same-day KR market snapshot, and KR Meta Screener as of 2026-11-05. This post is market analysis and does not constitute investment advice.